Registration 333-298621
S-4 · 2026-08-28 · 0001193125-26-374324
Terms from the governing filing for this registration; not a claim that the offering is open today.
Company research
Talawar Tx Inc.
CIK 2140859
Filing activity
Latest filing
6 filings on record · 425, S-4.
About the company
Talawar Therapeutics is a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent disease drivers in a single therapy, targeting pathways that work together for greater, more durable impact. Our lead program, TALA-125, is a novel anti-IL-13 x anti-IL-18 bispecific that combines two clinically validated, largely orthogonal mechanisms designed to shatter the current limitations of existing treatments - with broad applicability across first-line patients and those who have failed previous therapies.
Recent filings
Show 1 more recent filings
Offerings
Registration 333-298621
Filing attachments
tlwr-ex99_1.htm · S-4 · 2026-08-28
EX-99.1 8 tlwr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CONSENT OF HOULIHAN CAPITAL, LLC We hereby consent to the inclusion of our opinion letter to the Board of Directors of JATT II Acquisition Corp (“JATT”) as an exhibit to the Registration Statement on Form S-4 as filed by JATT with the Securities and Exchange Commission, and to the references to our firm and such opinion in such Registration Statement. In giving such consent, we do not admit, and we disclaim, that we come within the ca…
Read attachment ↗d136998dex991.htm · 425 · 2026-06-29
EX-99.1 8 d136998dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases Oversubscribed $225 million concurrent private investment in public equity (“PIPE”) with available cash to the combined company at closing anticipated to fund TALA-125 through a Phase 2b proof-of-concept study data rea…
Read attachment ↗d136998dex992.htm · 425 · 2026-06-29
EX-99.2 9 d136998dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Corporate Presentation June 2026 Disclaimer and forward-looking statements This confidential presentation has been made available to you for informal purposes only with the consent of Talawar Tx Inc. (the “Company” or Talawar ) and JATT II Acquisition Corp (“JATT”) and has been prepared to assist interested parties in making their own evaluation wi th respect to a business combination between the Company and JATT and related transact…
Read attachment ↗